Comprehensive Clinical Guide: Endoscopic Submucosal Dissection (ESD) of the Stomach (Body/Fundus)

1. Introduction and Overview

Endoscopic Submucosal Dissection (ESD) represents the gold standard for the minimally invasive treatment of early-stage gastric neoplasia. Specifically, when targeting lesions located in the gastric body or fundus, ESD allows for the en-bloc resection of tumors regardless of their size, provided they are confined to the mucosal layer or have minimal submucosal invasion.

Unlike traditional Endoscopic Mucosal Resection (EMR), which is often limited to small, piecemeal resections, ESD utilizes specialized electrosurgical knives to dissect the submucosal layer directly. This technique significantly reduces recurrence rates and provides high-quality histological specimens for accurate pathological staging. In the gastric body and fundus, the procedure presents unique anatomical challenges, including the curvature of the stomach, the thickness of the muscularis propria, and the proximity to major vascular structures.

2. Deep-Dive: Technical Specifications and Mechanisms

ESD is a complex, multi-stage endoscopic intervention. The fundamental mechanism relies on the creation of a "fluid cushion" within the submucosa, which lifts the lesion away from the muscularis propria, creating a safety buffer for dissection.

The Procedural Sequence:

1. Marking: Utilizing a snare tip or coagulation forceps, the clinician places circumferential dots approximately 5–10 mm outside the lesion boundary.
2. Injection: A lifting agent (e.g., sodium hyaluronate, glycerol, or saline with epinephrine/indigo carmine) is injected into the submucosa to elevate the lesion.
3. Incision: An initial mucosal incision is made using an electrosurgical knife (e.g., DualKnife, HookKnife, or IT-Knife).
4. Dissection: The submucosal layer is systematically dissected to separate the lesion from the muscularis propria.
5. Hemostasis: Active bleeding is controlled using coagulation forceps or hemoclips.

Anatomical Considerations for Body/Fundus:

• The Fundus: Characterized by a thinner wall, the fundus requires extreme caution to avoid perforation. The retroflexed position is often necessary to achieve a perpendicular approach to the lesion.
• The Gastric Body: The body offers a larger luminal space, facilitating maneuverability. However, the greater curvature is prone to higher vascularity, necessitating aggressive prophylactic hemostasis.

3. Clinical Indications and Usage

ESD is indicated for lesions where the risk of lymph node metastasis is negligible. The following table outlines the current clinical criteria for gastric ESD.

4. Patient Pre-Operative Preparation

Success in ESD is heavily dependent on meticulous preparation.

• Pre-procedure Assessment: Patients must undergo high-resolution white-light endoscopy with Narrow Band Imaging (NBI) or Blue Light Imaging (BLI) to define lesion margins. An EUS (Endoscopic Ultrasound) may be performed to rule out deep submucosal invasion or lymph node involvement.
• Medication Management: Antiplatelet and anticoagulant therapy must be managed according to the patient's cardiovascular risk profile. Typically, aspirin may be continued, while P2Y12 inhibitors and direct oral anticoagulants (DOACs) are held 3–7 days pre-procedure.
• Anesthesia: ESD is performed under deep sedation or general anesthesia with endotracheal intubation to protect the airway and ensure patient immobility.

5. Post-Operative Recovery and Protocol

The post-ESD recovery phase is critical for detecting delayed complications, such as perforation or secondary hemorrhage.

1. Immediate Post-Op: Monitoring of vital signs and observation for signs of peritonitis (e.g., abdominal pain, fever, tachycardia).
2. Dietary Progression: Patients are typically kept NPO (nothing by mouth) for 12–24 hours, followed by a liquid diet, and transitioning to a soft diet by day 3.
3. Proton Pump Inhibitor (PPI) Therapy: High-dose PPIs are administered intravenously for 24–48 hours, followed by oral therapy for 4–8 weeks to facilitate ulcer healing and prevent post-ESD bleeding.
4. Follow-up: A follow-up endoscopy is usually scheduled at 6–12 months to confirm complete healing and ensure no recurrence.

6. Potential Complications

While ESD is highly effective, it carries inherent risks that the medical team must manage:

• Intraprocedural Bleeding: Common; managed via coagulation forceps or clips.
• Delayed Bleeding: Occurs in 3–5% of cases, typically within the first 72 hours.
• Perforation: More common in the fundus due to the thin gastric wall. Managed with endoscopic clip closure or, in rare cases, surgical intervention.
• Stricture: Extremely rare in the stomach compared to the esophagus, unless the resection involves the cardia or pylorus.

7. Alternative Treatments

While ESD is the gold standard, alternative approaches exist based on tumor staging:

• Endoscopic Mucosal Resection (EMR): Suitable only for small (<10mm) non-ulcerated lesions.
• Laparoscopic-Endoscopic Cooperative Surgery (LECS): Used for gastric GISTs or lesions where the risk of perforation is high, combining endoscopic resection with laparoscopic guidance.
• Surgical Gastrectomy: Indicated for lesions with deep submucosal invasion (SM2+), lymph node involvement, or suspected malignancy beyond endoscopic criteria.

8. Massive FAQ Section

Q1: How long does a gastric ESD procedure typically take?
A: Depending on the size, location, and presence of fibrosis, the procedure typically lasts between 60 and 180 minutes.

Q2: What is the success rate of ESD for gastric neoplasia?
A: En-bloc resection rates for gastric ESD are consistently reported above 95% in experienced centers.

Q3: Can ESD be performed on patients taking blood thinners?
A: It depends on the risk of thrombosis. In many cases, bridging therapy or temporary suspension of antiplatelet agents is required.

Q4: How painful is the recovery process?
A: Most patients experience mild-to-moderate abdominal discomfort for 24–48 hours, which is managed with standard analgesics.

Q5: What are the signs of a post-ESD perforation?
A: Severe, persistent abdominal pain, rigid abdomen, fever, and symptoms of systemic inflammation.

Q6: Why is the fundus considered more difficult than the antrum?
A: The fundus wall is significantly thinner (approx. 2–3 mm), increasing the risk of thermal injury to the serosa during electrosurgical dissection.

Q7: Will I need to stay in the hospital overnight?
A: Yes, standard protocol requires at least 24–48 hours of inpatient observation to monitor for delayed complications.

Q8: What is the recurrence rate after successful ESD?
A: With R0 (curative) resection, the recurrence rate is less than 1%.

Q9: Can ESD be used for gastric GISTs?
A: Yes, specifically for small GISTs (usually <20mm). However, these require specific endoscopic techniques as they originate from the muscularis propria.

Q10: What is the difference between R0 and R1 resection?
A: R0 signifies complete resection with clear lateral and vertical margins. R1 signifies positive margins, which may necessitate further treatment or surgery.

9. Conclusion

ESD of the gastric body and fundus is a sophisticated procedure that requires a high level of technical expertise and a deep understanding of gastric anatomy. By adhering to strict patient selection criteria and rigorous post-operative protocols, clinicians can offer patients a definitive, organ-sparing cure for gastric neoplasia. As endoscopic technology continues to evolve with improved electrosurgical knives and traction devices, the safety and efficacy of ESD will continue to improve, cementing its role as the premier modality in gastroenterology.

Disclaimer: This guide is for educational purposes for healthcare professionals. Clinical decisions should always be based on institutional guidelines, patient-specific factors, and the expertise of the attending gastroenterologist/surgeon.